Van Den Brink; Edward
Patent Applications and Registrations
Patent applications and USPTO patent grants for Van Den Brink; Edward.The latest application filed is for "bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof".
Company Profile
30.17.30
- Van Den Brink; Edward - Utrecht NL
- VAN DEN BRINK; Edward - Halfweg NL
Patent Activity
| Patent | Date |
|---|---|
| Agents, uses and methods for the treatment of synucleinopathy Grant 11,421,024 - Kallunki , et al. August 23, 2 | 2022-08-23 |
| Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20220251231 - OOSTINDIE; Simone ; et al. | 2022-08-11 |
| Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof Grant 11,396,553 - Oostindie , et al. July 26, 2 | 2022-07-26 |
| Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20210355232 - OOSTINDIE; Simone ; et al. | 2021-11-18 |
| Agents, Uses And Methods For Treatment App 20210292414 - Biilmann Ronn; Lars Christian ; et al. | 2021-09-23 |
| Agent, Uses And Methods For Treatment App 20210269524 - Biilmann Ronn; Lars Christian ; et al. | 2021-09-02 |
| Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof Grant 11,034,772 - Oostindie , et al. June 15, 2 | 2021-06-15 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210147522 - KALLUNKI; Pekka ; et al. | 2021-05-20 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210061892 - KALLUNKI; Pekka ; et al. | 2021-03-04 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20210054057 - KALLUNKI; Pekka ; et al. | 2021-02-25 |
| Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20210024647 - OOSTINDIE; Simone ; et al. | 2021-01-28 |
| Agents, uses and methods for treatment Grant 10,894,833 - Biilmann Ronn , et al. January 19, 2 | 2021-01-19 |
| Agent, uses and methods for treatment Grant 10,889,650 - Biilmann Ronn , et al. January 12, 2 | 2021-01-12 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20200397913 - BOSHUIZEN; Julia ; et al. | 2020-12-24 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,800,836 - Kallunki , et al. October 13, 2 | 2020-10-13 |
| Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20200291124 - OOSTINDIE; Simone ; et al. | 2020-09-17 |
| Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20200270359 - OOSTINDIE; Simone ; et al. | 2020-08-27 |
| Antibodies Against Pd-l1 App 20200239579 - ALTINTAS; Isil ; et al. | 2020-07-30 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20200199231 - ENGELBERTS; Patrick ; et al. | 2020-06-25 |
| Agent, Uses And Methods For Treatment App 20200190188 - Biilmann Ronn; Lars Christian ; et al. | 2020-06-18 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,763 - Kallunki , et al. | 2020-05-12 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,647,764 - Kallunki , et al. | 2020-05-12 |
| Agents, uses and methods for the treatment of synucleinopathy Grant 10,640,554 - Kallunki , et al. | 2020-05-05 |
| Humanized Or Chimeric Cd3 Antibodies App 20200123255 - VAN DEN BRINK; Edward ; et al. | 2020-04-23 |
| Bispecific antibodies against CD3 and CD20 Grant 10,544,220 - Engelberts , et al. Ja | 2020-01-28 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190382473 - KALLUNKI; Pekka ; et al. | 2019-12-19 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367594 - KALLUNKI; Pekka ; et al. | 2019-12-05 |
| Agents, Uses And Methods For The Treatment Of Synucleinopathy App 20190367595 - Kallunki; Pekka ; et al. | 2019-12-05 |
| Agent, uses and methods for treatment Grant 10,479,835 - Biilmann Ronn , et al. Nov | 2019-11-19 |
| Humanized or chimeric CD3 antibodies Grant 10,465,006 - Van Den Brink , et al. No | 2019-11-05 |
| Anti-sortilin antibodies, uses and methods for treatment Grant 10,428,147 - Biilmann Ronn , et al. October 1, 2 | 2019-10-01 |
| Antibodies for the treatment of synucleinopathy Grant 10,364,285 - Kallunki , et al. | 2019-07-30 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,484 - Kallunki , et al. July 23, 2 | 2019-07-23 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,483 - Kallunki , et al. July 23, 2 | 2019-07-23 |
| Antibodies for the treatment of synucleinopathy Grant 10,358,482 - Kallunki , et al. | 2019-07-23 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20190022243 - BOSHUIZEN; Julia ; et al. | 2019-01-24 |
| Agents, Uses And Methods For Treatment App 20190023788 - Ronn; Lars Christian Biilmann ; et al. | 2019-01-24 |
| Axl-specific Antibody-drug Conjugates For Cancer Treatment App 20180326084 - BOSHUIZEN; Julia ; et al. | 2018-11-15 |
| Agent, Uses And Methods For Treatment App 20180305455 - Biilmann Ronn; Lars Christian ; et al. | 2018-10-25 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179270 - Kallunki; Pekka ; et al. | 2018-06-28 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180179271 - Kallunki; Pekka ; et al. | 2018-06-28 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127492 - Kallunki; Pekka ; et al. | 2018-05-10 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20180127491 - Kallunki; Pekka ; et al. | 2018-05-10 |
| Bispecific Antibodies Against Cd3 And Cd20 App 20170355767 - ENGELBERTS; Patrick ; et al. | 2017-12-14 |
| Agents, Uses and Methods for Treatment App 20170267761 - Biilmann Ronn; Lars Christian ; et al. | 2017-09-21 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy App 20170015739 - Kallunki; Pekka ; et al. | 2017-01-19 |
| Humanized Or Chimeric Cd3 Antibodies App 20160168247 - VAN DEN BRINK; Edward ; et al. | 2016-06-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 